Topics

Amylin and Obesity Treatment

Metabolic Diseases Diabetes Intercellular Communication & Diseases

Amylin, also called islet amyloid polypeptide, is a pancreatic β-cell hormone co-secreted with insulin in response to nutrient stimuli and is an important physiological regulator of metabolic control. Research over roughly 35 years has established amylin as a meal-ending satiation signal that also limits gastric emptying and reduces pancreatic glucagon secretion, particularly after meals. These properties made the amylin pathway relevant first to diabetes therapy and subsequently to obesity pharmacotherapy. The synthetic analogue pramlintide demonstrated that pharmacological amylin replacement could improve glycemic control while reducing body weight in insulin-treated type 2 diabetes, although its short-acting profile requires mealtime administration. More recent research has therefore focused on long-acting amylin receptor agonists suitable for sustained weight management, moving the pathway from metabolic physiology toward a major anti-obesity drug-development strategy[1][2].

Amylin acts primarily through direct brain activation, with the caudal hindbrain having a prominent role in its metabolic effects. Amylin receptors consist of the calcitonin receptor together with receptor activity-modifying proteins, creating receptor complexes that mediate effects on satiation, gastric emptying and glucagon secretion. Recent mechanistic work with cagrilintide strengthens this receptor model: amylin binds heterodimeric receptors composed of the calcitonin receptor and RAMP1, RAMP2 or RAMP3, while experiments in RAMP1/3-knockout mice showed that loss of these components reduced cagrilintide potency for body-weight lowering. Cagrilintide also activated neurons in the dorsal vagal complex and lateral parabrachial nucleus, and its area-postrema neuronal response was diminished when RAMP1 and RAMP3 were absent. These findings connect molecular amylin-receptor architecture with central neural circuits governing food intake and body weight[1][3].

Clinical development now centers on long-acting amylin agonism for obesity and on combining amylin signaling with complementary metabolic pathways. In a phase 2 trial involving people with overweight or obesity without diabetes, once-weekly cagrilintide produced mean body-weight reductions of 6.0-10.8% after 26 weeks across tested doses, versus 3.0% with placebo; the 4.5-mg dose also produced greater weight reduction than liraglutide 3.0 mg. Gastrointestinal disorders, including nausea, constipation and diarrhea, were the most frequent adverse events. Combination treatment has provided another application: in a phase 1b trial, cagrilintide given with semaglutide 2.4 mg produced mean weight reductions reaching 17.1% at week 20, while most adverse events were mild to moderate. Earlier pramlintide studies additionally support amylin pharmacology for simultaneous glycemic and weight control in insulin-treated type 2 diabetes[2][4][5].

Important research gaps remain in receptor selectivity, tolerability, pharmacokinetics and translation of mechanistic findings into durable clinical benefit. Complex receptor biology and the short half-life and amyloid-forming propensity associated with native amylin have complicated therapeutic development, while clinical trials show that gastrointestinal adverse events remain relevant for long-acting approaches. Selective agonism is consequently an active direction. Eloralintide preferentially activated human AMY1R over calcitonin receptor and AMY3R in translational studies, showed favorable pharmacokinetics supporting once-weekly administration, and produced dose-dependent reductions in food intake and body weight in preclinical models; early clinical testing also showed body-weight reduction after single doses. Future research should therefore define which amylin-receptor activation profiles optimize efficacy and gastrointestinal tolerability, determine how central receptor circuits translate to human weight control, and establish the long-term efficacy and safety of selective agonists and amylin-based combination therapies[1][5][6].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-P0035A Insulin solution (human)
Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus.
Insulin Receptor  
Metabolic or Endocrine Disease  
105
HY-P0035 Insulin (human)
Insulin (human) is a polypeptide hormone that regulates the level of glucose. Insulin (human) can be used for the diabetes mellitus.
Insulin Receptor  
Metabolic or Endocrine Disease  
105
HY-L012 Metabolism/Protease Compound Library
Metabolism is the set of life-sustaining chemical reactions in organisms. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. Acting as catalysts, enzymes are crucial to metabolism - they allow a reaction to proceed more rapidly - and they also allow the regulation of the rate of a metabolic reaction. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Imbalances in metabolic activities have been found to be critical in a number of pathologies, such as cardiovascular diseases, inflammation, cancer, and neurodegenerative diseases. MCE designs a unique collection of 7,360 Metabolism/Protease-related small molecules that act as a useful tool for drug discovery of metabolism-related diseases.

Signaling Pathway Targeting Libraries

89
HY-L040 Anti-diabetic Compound Library
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Disease Focused Libraries

84
HY-L087 Anti-Obesity Compound Library
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,741 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Disease Focused Libraries

83
HY-L103 Anti-Colorectal Cancer Compound Library
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,653 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L199 Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 5,024 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.
83
HY-L265 Cholesterol Metabolism Compound Library
Cholesterol is a crucial lipid that maintains cell membrane structure, serves as a precursor for the synthesis of steroid hormones and bile acids, and plays an important role in cell signal transduction and membrane function regulation. Intracellular cholesterol levels are precisely controlled by multiple processes, including synthesis, uptake, transport, esterification, storage, and efflux. Dysregulation of cholesterol metabolism is closely associated with diseases such as atherosclerosis, fatty liver disease, metabolic syndrome, and various cancers. The Cholesterol Metabolism Compound Library contains 558 compounds and focuses on cholesterol metabolism and homeostatic regulation. It provides an efficient tool for mechanistic studies of cholesterol metabolism and for drug discovery in metabolism‑related diseases.
83
HY-10191 Linsitinib
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively.
IGF-1R   Insulin Receptor  
Lung Cancer   Prostate Cancer   Pancreatic Cancer   Glucose Metabolism   SARS-CoV-2 Infection  
52
HY-114118B Semaglutide acetate
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118A Semaglutide TFA
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-15656A Ceritinib dihydrochloride
Ceritinib (LDK378) dihydrochloride is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib dihydrochloride also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride shows great antitumor potency.
Anaplastic lymphoma kinase (ALK)   Insulin Receptor   IGF-1R  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Non-Small Cell Lung Cancer  
43
HY-15656 Ceritinib
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
Anaplastic lymphoma kinase (ALK)   Insulin Receptor   IGF-1R  
Metabolic or Endocrine Disease   Respiratory Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Non-Small Cell Lung Cancer  
43
HY-P0014 Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Parkinson's Disease   Type 1 Diabetes   Psoriasis   Chronic Obstructive Pulmonary Disease   Type 2 Diabetes   Obesity  
43
HY-N0055 Chlorogenic acid
Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb. It is an orally active antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension compound.
HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   Bacterial   Influenza Virus   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Breast Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Cardiovascular Disease   Obesity  
38
HY-15494 Picropodophyllin
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
IGF-1R   Apoptosis  
Metabolic or Endocrine Disease   Prostate Cancer   Pancreatic Cancer   Digestive System Inflammation   SARS-CoV-2 Infection  
31
HY-N0114 Evodiamine
Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor.
Others  
Cancer   Obesity  
20
HY-17365 Octreotide acetate
Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.
Somatostatin Receptor  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
17
HY-P1156 Insulin(cattle)
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.
Insulin Receptor  
Metabolic or Endocrine Disease  
17
HY-N2302 Fucoxanthin
Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
Bacterial   PPAR   c-Myc   NO Synthase   Caspase   ERK  
Pancreatic Cancer   Bacterial Infection   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis  
15
HY-P0082A Glucagon (1-29), bovine, human hydrochloride
Glucagon (1-29), bovine, human, porcine hydrochloride is a peptide hormone, produced by pancreatic α-cells. Glucagon hydrochloride stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine hydrochloride activates HNF4α and increases HNF4α phosphorylation.
GCGR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
14
HY-50866 NVP-AEW541
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 has antitumor activity.
IGF-1R   Insulin Receptor   Autophagy  
Metabolic or Endocrine Disease   Prostate Cancer   Pancreatic Cancer  
14
HY-10200 BMS-754807
BMS-754807 is a potent and reversible IGF-1R/IR inhibitor (IC50=1.8 and 1.7 nM, respectively; Ki=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC50 values of 6, 44, 7, 4, 9, and 25 nM, respectively.
IGF-1R   Insulin Receptor  
Metabolic or Endocrine Disease   Lung Cancer   Prostate Cancer   Pancreatic Cancer   Pain  
14
HY-P0082 Glucagon (1-29), bovine, human
Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation.
GCGR  
Cancer   Metabolic or Endocrine Disease  
14
HY-106224B Orexin A (human, rat, mouse) acetate
Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease  
13
HY-N0828 Pterostilbene
Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties. Pterostilbene blocks ROS production, also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide.
Free Radical Scavengers   Autophagy  
Pancreatic Cancer   Glucose Metabolism   Antioxidant Agent   Hypertension   Obesity  
12
HY-N0644 Carnosic acid
Carnosic acid is an orally active lipid absorption inhibitor. Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity.
Apoptosis   Bacterial  
Cancer   Bacterial Infection   Neurodegenerative Disease   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
10
HY-N1411 Platycodin D
Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D.
AMPK   Wnt  
Pancreatic Cancer   Pain   Digestive System Inflammation   Obesity  
9
HY-14860A 1-Deoxynojirimycin hydrochloride
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features.
Glycosidase   PI3K   Bacterial   Antibiotic  
Breast Cancer   Pancreatic Cancer   Bacterial Infection   Depression   Pain   Glucose Metabolism   Obesity  
7
HY-14860 1-Deoxynojirimycin
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features.
Glycosidase   PI3K  
Breast Cancer   Pancreatic Cancer   Depression   Pain   Glucose Metabolism   SARS-CoV-2 Infection   Obesity  
7
HY-N0022 Isoacteoside
Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside regulates the AKT/PI3K/m-TOR/NF-κB signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities.
Apoptosis   Reactive Oxygen Species (ROS)   Akt   mTOR   PI3K   NO Synthase   COX   p38 MAPK   Toll-like Receptor (TLR)   Amyloid-β  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Alzheimer's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
7
HY-N0330 Momordin Ic
Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity.
Apoptosis   Autophagy   PI3K   c-Myc  
Breast Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Glucose Metabolism   Rheumatoid Arthritis  
5
HY-W087937 Benzamidine hydrochloride hydrate
Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride hydrate effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride hydrate undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride hydrate only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride hydrate may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride hydrate can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results.
Ser/Thr Protease  
Cancer  
4
HY-142812 GRK6-IN-1
GRK6-IN-1 (Compound 18) is the inhibitor for G protein-coupled receptorkinase 6 (GRK6) with an IC50 of 3.8-8 nM. GRK6-IN-1 also inhibits GRK7, GRK5, GRK4 and GRK1 with IC50s of 6.4, 12, 22 and 52 nM, respectively. GRK6-IN-1 has the potential for the research of multiple myeloma.
G Protein-coupled Receptor Kinase (GRK)   Aurora Kinase   IGF-1R  
Neurological, Eye or Ear Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer  
4
HY-N0547 Nomilin
Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .
Others  
Obesity  
3
HY-P10138A human GIP(3-30), amide TFA
Human GIP(3-30), amide TFA is the TFA salt form of human GIP(3-30), amide (HY-P10138). Human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide TFA has potential anti-obesity and anti-diabetic effects.
Insulin Receptor  
Metabolic or Endocrine Disease  
3
HY-P3506A Retatrutide TFA
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity.
GLP Receptor   GCGR  
Metabolic or Endocrine Disease  
3
HY-N4103 Fucosterol
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities. Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research.
PARP   Endogenous Metabolite  
Breast Cancer   Ovarian Cancer   Glucose Metabolism   Obesity  
3
HY-B0149 Tranexamic acid
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 (HY-172590)).
IGF-1R   AMPK   MMP   Mitophagy  
Breast Cancer   Melanoma   Ovarian Cancer   Epilepsy   Brain Hemorrhage  
3
HY-107542 Oleoylethanolamide
Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
Endogenous Metabolite   PPAR  
Metabolic or Endocrine Disease   Digestive System Disease   Depression   Digestive System Inflammation   Cardiovascular Disease  
3
HY-P10138 human GIP(3-30), amide
Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects.
Insulin Receptor  
Metabolic or Endocrine Disease  
3
HY-P3462A Cagrilintide acetate
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies.
CGRP Receptor  
Metabolic or Endocrine Disease  
3
HY-P0090 Calcitonin (salmon)
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
CGRP Receptor  
Cancer  
3
HY-P0276 GIP, human
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.
Insulin Receptor  
Metabolic or Endocrine Disease  
3
HY-P3462 Cagrilintide
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.
CGRP Receptor  
Metabolic or Endocrine Disease  
3
HY-P3506 Retatrutide
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
GCGR   GLP Receptor  
Obesity  
3
HY-19884B Relamorelin TFA
Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
GHSR  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
2
HY-N4170 Chebulic acid
Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection.
Keap1-Nrf2   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis  
2
HY-P1339B Orexin B, human acetate
Orexin B, human acetate is the acetate form of Orexin B, human (HY-P1339). Orexin B, human acetate is the agonist for Orexin Receptor, with Ki of 420 nM and 36 nM for OX1 and OX2. Orexin B, human acetate participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
2
HY-P70239 GLP-1/GCG Protein, Human (HEK293, His)
GLP-1 and GCG are two proteins derived from the same precursor protein, which is encoded by the GCG-glucagon gene. The GCG protein is a counterregulatory hormone to insulin, playing a crucial role in glucose metabolism by increasing gluconeogenesis and reducing glycolysis to regulate blood glucose levels. GLP-1 protein, secreted by intestinal endocrine cells, promotes insulin secretion, regulates gastrointestinal motility, and inhibits the secretion of GCG protein. GLP-1/GCG protein, Human (HEK293, His), is a recombinant GLP-1/GCG protein expressed by HEK293 cells, with a His tag at the C-terminus, and is composed of 160 amino acids (R21-K180).

Species: Human; Source: HEK293

Cytokines and Growth Factors Peptide Hormone & Neuropeptides GLP-1

2
HY-P81160 GLP-1R Antibody
GLP-1R Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GLP-1R.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

2
HY-119739 Skyrin
Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells.
GCGR  
Metabolic or Endocrine Disease  
1
HY-N0644R Carnosic acid (Standard)
Carnosic acid (Standard) is the analytical standard of Carnosic acid. This product is intended for research and analytical applications. Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity.
Apoptosis   Reference Standards   Bacterial  
Cancer   Bacterial Infection   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
1
HY-P3291 Dapiglutide
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects.
GCGR  
Metabolic or Endocrine Disease  
1
HY-P3463 Beinaglutide
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
GCGR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-N0923 Corydaline
Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities.
Cholinesterase (ChE)   Enterovirus   Opioid Receptor  
Cancer   Viral Infection   Depression   Pain  
1
HY-P99165 Teprotumumab
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research.

Species: Human

IGF-1R   TSH Receptor  
Metabolic or Endocrine Disease  
1
HY-P99294 Ganitumab
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.

Species: Human

IGF-1R  
Breast Cancer   Non-Small Cell Lung Cancer  
1
HY-108810 Canakinumab
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Pancreatic Cancer   Non-Small Cell Lung Cancer   SARS-CoV-2 Infection   Type 2 Diabetes  
1
HY-P1464 Amylin, amide, rat
Amylin, amide, rat is a potent and high affinity ligand of Amylin receptor AMY1 and AMY3 receptors and variably of AMY2 receptors; binding studies are generally used for the latter receptor.
Amylin Receptor  
Metabolic or Endocrine Disease  
1
HY-P11274 Zenagamtide
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   GCGR   Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-15498S Rimegepant-d4
Rimegepant-d4 (BMS-927711-d4) is the deuterium labeled Rimegepant (HY-15498). Rimegepant (BMS-927711) is an orally bioavailable and blood-brain barrier permeable antagonist of CGRP and AMY1 receptors, with a pIC50 of 8.01 and a Ki of 0.027 nM for human CGRP receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at CGRP and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to migraine.
Isotope-Labeled Compounds   CGRP Receptor  
Neurological, Eye or Ear Disease  
/
HY-N21938 7-Acetyllycopsamine N-oxide
7-Acetyllycopsamine N-oxide is a pyrrolizidine alkaloid N-oxide (PA N-oxide) that can be extracted from plants such as those in the Boraginaceae, Asteraceae or Compositae families. 7-Acetyllycopsamine N-oxide acts as a metabolic and potential toxic precursor. 7-Acetyllycopsamine N-oxide can be used in studies on component quantitative analysis, quality control of traditional Chinese medicine, and toxicological risk assessment for public health.
Endogenous Metabolite  
/
HY-111614S Melengestrol acetate-d6
Melengestrol acetate-d6 is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research.
Isotope-Labeled Compounds   Progesterone Receptor  
Metabolic or Endocrine Disease  
/
HY-P1841 Glucagon-Like Peptide (GLP) II, human
Glucagon-Like Peptide (GLP) II, human is a 33-amino acid peptide derived from the C-terminal of proglucagon and mainly produced by the intestinal L cells. Glucagon-Like Peptide (GLP) II, human stimulates intestinal mucosal growth and decreases apoptosis of enterocytes .
Endogenous Metabolite   Apoptosis  
Metabolic or Endocrine Disease  
/
HY-P1339AS Orexin B, human-13C6,15N TFA
Orexin B, human-13C6,15N (Human orexin B-13C6,15N) TFA is the 13C- and 15N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with Kis of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine.
Isotope-Labeled Compounds   Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P11670 Linvixdutide
Linvixdutide is a glucagon and glucagon-like peptide 1 receptor (GLP-1R) agonist with anti-obesity effects.
GLP Receptor  
Obesity  
/
HY-N0923R Corydaline (Standard)
Corydaline (Standard) is the analytical standard of Corydaline. This product is intended for research and analytical applications. Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities.
Reference Standards   Cholinesterase (ChE)   Enterovirus   Opioid Receptor  
Neurological, Eye or Ear Disease  
/
HY-N19062 Caralluma fimbriata extract
Caralluma fimbriata extract is often used to suppress appetite and aid in weight management.
Others  
Metabolic or Endocrine Disease  
/
HY-P992006 Anti-Glucagon Antibody
Anti-Glucagon Antibody is an anti-Glucagon antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

GCGR  
/
HY-N10114 Hyperectumine
Hyperectumine exhibits moderate anti-inflammatory activity via suppression of LPS-activated inflammatory mediators in RAW 264.7 macrophage cells.
Others  
Inflammation or Immune System Disease  
/
HY-N0330R Momordin Ic (Standard)
Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity.
Reference Standards   Apoptosis   Autophagy   PI3K   c-Myc  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N2840S Allitol-13C
Allitol (Allodulcitol)-13C is the 13C labeled Allitol (HY-N2840). Allitol is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes.
Isotope-Labeled Compounds  
Metabolic or Endocrine Disease  
/
HY-113261S1 Oleoylcarnitine-13C,d3
Oleoylcarnitine-13C,d3 is the deuterium and 13C-labeled Oleoylcarnitine (HY-113261). Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-14472S1 Tesofensine-13C,d3
Tesofensine-13C,d3 (NS-2330-13C,d3) is the deuterium and 13C-labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
Isotope-Labeled Compounds   Dopamine Transporter   Serotonin Transporter  
Metabolic or Endocrine Disease  
/
HY-N18773 Coleus forskohlii extract
Coleus forskohlii extract can promote fat reduction and improve weight management, and also has the effect of lowering blood pressure and improving blood circulation, thereby maintaining heart health.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P2025 JMV 236
JMV 236 is a cholecystokinin antagonist with appetite-suppressing activity. JMV 236 affects the regulation of food intake through the interaction of the intestinal endogenous peptide PrRP and the CCK1 receptor. The administration of JMV 236 activates PrRP neurons located in the NTS, thereby enhancing its appetite-suppressing effect. JMV 236 has significant effects on areas of the central nervous system associated with food intake, especially during states of starvation.
Histone Methyltransferase  
Neurological, Eye or Ear Disease  
/
HY-N6629R 3'-Methoxyflavonol (Standard)
Prednisolone acetate (Standard) is the analytical standard of Prednisolone acetate. This product is intended for research and analytical applications. Prednisolone acetate (Prednisolone 21-acetate) is an adrenocortical hormone active molecule with various pharmacological effects such as anti-inflammatory, anti-allergic, and immune suppression.
Neuromedin U Receptor (NMUR)   Reference Standards  
Neurological, Eye or Ear Disease  
/
HY-14472S Tesofensine-d5
Tesofensine-d5 (NS-2330-d5) is the deuterium labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
Isotope-Labeled Compounds   Dopamine Transporter   Serotonin Transporter  
Metabolic or Endocrine Disease  
/
HY-P991248 TTX-080
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC).

Species: Human

Others  
Cancer  
/
HY-W002116S Methyl syringate-d6
Methyl syringate-d6 is the deuterium labeled Methyl syringate. Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis.
TRP Channel   COX   Phosphatase   Bacterial  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-D3173 TP-α
TP-α (TPG-456) is a glucagon-selective two-photon fluorescent probe with a Kd of 65 μM. TP-α directly interacts with glucagon to produce significant fluorescence enhancement. TP-α selectively stains viable glucagon-secreting α cells in pancreatic islets, enabling visualization of their localization, distribution and availability. TP-α is applicable to diabetes research (Ex/Em = 370nm/510 nm).
Fluorescent Dye   GCGR  
Glucose Metabolism  
/
HY-W720961 Dimethachlor-d6
Dimethachlor-d6 is the deuterium labeled Dimethachlor (HY-121423). Dimethachlor, a synthetic herbicide, inhibits the undesirable growth of weeds via the suppression of very long-chain fatty acid synthesis. Dimethachlor disrupts normal developmental processes via the induction of apoptosis and ROS production.
Reactive Oxygen Species (ROS)  
Metabolic or Endocrine Disease  
/
HY-P11245 NN1213
NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity.
Amylin Receptor  
Obesity  
/
HY-B1890S (±)-Catechin-13C3
(±)-Catechin-13C3 (rel-Cianidanol-13C3) is the 13C-labeled (±)-Catechin (HY-B1890). (±)-Catechin (rel-Cianidanol) is the racemate of the green tea polyphenol Catechin. Catechin has anticancer activity and induces apoptosis. (±)-Catechin has two forms, (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. (-)-Catechin can effectively promote hBM-MSC adipocyte differentiation and increase adiponectin and PPARγ levels. (±)-Catechin has anti-tumor, anti-obesity, anti-diabetic, anti-cardiovascular, anti-infectious, hepatoprotective and neuroprotective effects.
Isotope-Labeled Compounds   COX  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P991249 NI-203
NI-203 is a monoclonal antibody inhibitor that targets amylin. NI-203 is promising for research of type 2 diabetes.

Species: Human

Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-101021 Ascochlorin
Ascochlorin (Ilicicolin D), an isoprenoid antibiotic, mediates its anti-tumor effects predominantly through the suppression of STAT3 signaling cascade. Ascochlorin induces apoptosis. Anti-inflammatory activity.

Source: Ascochyta viciae

STAT   Apoptosis   Antibiotic  
Inflammation or Immune System Disease  
/
HY-N11827 Isocorybulbine
Isocorybulbine ((+)-Isocorybulbine) is one of the main metabolites of Corydaline (HY-N0923) in human liver microsomes and liver cells. Corydaline has anti-acetylcholinesterase, anti-allergic, anti-allergic reaction and gastric emptying activities. Isocorybulbine can be used for the metabolic study of Corydaline.
Drug Metabolite  
/
HY-D3172 BD-105
BD-105 (Glucagon Yellow) is a glucagon-binding fluorescent probe with a KD value of 13.3 μM. BD-105 exhibits changes in fluorescence intensity upon interaction with glucagon, and colocalizes with glucagon in cells and tissues. BD-105 is a selective cell stain that labels glucagon-secreting cells without staining insulin-secreting cells or non-endocrine control cells. BD-105 serves as an imaging reagent for glucagon in live cells and tissues (Ex/Em = 540 nm/580 nm).
Fluorescent Dye  
Metabolic or Endocrine Disease  
/
HY-N2692 6,8-Diprenylgenistein
6,8-Diprenylgenistein is an isoflavone compound isolated from Cudrania tricuspidata. 6,8-Diprenylgenistein has antimicrobial and anti-obesity activity. 6,8-Diprenylgenistein inhibits the proliferation, migration and tubular formation of HLMEC induced by recombinant human vascular endothelial growth factor-A. 6,8-Diprenylgenistein can be used to study new therapeutic drugs for the prevention and treatment of oral cancer metastasis .
Bacterial  
Cancer  
/
HY-P992007 PF-06293620
PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus.

Species: Human

GCGR  
Type 2 Diabetes  
/
HY-111614S1 Melengestrol acetate-d2
Melengestrol acetate-d2 is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research.
Isotope-Labeled Compounds   Progesterone Receptor  
Metabolic or Endocrine Disease  
/
HY-P1297A CRF(6-33)(human) TFA
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect.
CRFR  
Neurological, Eye or Ear Disease  
/
HY-N15152 Isoaesculioside D
Isoaesculioside D (compound 3) is an agent for preventing or ameliorating skin aging. Isoaesculioside D exhibits an excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin.
Others  
Metabolic or Endocrine Disease  
/
HY-P0014AS Liraglutide-d8 tetraTFA
Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-Y0078S Cinnamyl Alcohol-d5
Cinnamyl Alcohol-d5 is deuterated labeled Cinnamyl Alcohole (HY-Y0045). Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, exhibits anti-obesity, antioxidant and anti-inflammatory activities.
Isotope-Labeled Compounds   Potassium Channel   NO Synthase   ERK   ROCK   AMPK   Akt   PPAR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-B1953S Thiacloprid-d4
Thiacloprid-d4 is the deuterium labeled Thiacloprid. Thiacloprid is an orally active neurotoxic insecticide and also a nAChR agonist. Thiacloprid reduces the viability of healthy cells, depletes reduced glutathione, and increases MDA levels, thereby inducing cytotoxicity and oxidative stress damage. In practical applications, Thiacloprid has lower acute toxicity to honeybees than other compounds of the same class such as Imidacloprid (HY-B0838), but it still significantly impairs the learning and memory function, immune capacity and survival status of honeybees. Thiacloprid induces intestinal microbial dysbiosis and reduces survival rate in middle-aged honeybees, increases the risk of premature collapse in bumblebee colonies, and significantly decreases the final colony weight and reproductive output. Thiacloprid is used in broad-spectrum agricultural pest control, often alone or in combination with Deltamethrin (HY-B1971), and meets the pest management needs of various crops including potatoes, cabbages, various fruits and vegetables, and nuts.
nAChR   Insecticide  
Infection  
/
HY-W115727D Polyacrylamide,average Mn 40000
Polyacrylamide (PAM), average Mn 40000 is a versatile, high-molecular-weight polyacrylamide copolymer. Polyacrylamide series materials can maintain enzyme activity in enzyme immobilization, act as drug carriers to achieve controlled release, serve as smart materials responding to temperature/pH stimuli, and be used for in vitro toxin adsorption and soft tissue filling through mechanisms such as physical entrapment, covalent binding or chemical crosslinking. Polyacrylamide finds applications in biomedical engineering, environmental management and industrial applications.
Biochemical Assay Reagents  
/
HY-W002116R Methyl syringate (Standard)
Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis.
Reference Standards   TRP Channel   COX   Phosphatase   Bacterial  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Bacterial Infection  
/
HY-N4170R Chebulic acid (Standard)
Chebulic acid (Standard) is the analytical standard of Chebulic acid (HY-N4170). This product is intended for research and analytical applications. Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection.
Reference Standards   Keap1-Nrf2   Reactive Oxygen Species (ROS)  
/
HY-W115727C Polyacrylamide,Nonionic,Mw 5-6 million
Polyacrylamide (Acrylamide polymer),Nonionic,Mw 5-6 million is a multifunctional, high-molecular-weight nonionic polyacrylamide copolymer. Polyacrylamide-based materials can maintain enzyme activity in enzyme immobilization, act as drug carriers for controlled release, function as smart materials responsive to temperature/pH stimuli, and be applied in in vitro toxin adsorption and soft tissue filling, through action mechanisms such as physical entrapment, covalent binding or chemical crosslinking. Polyacrylamide finds applications in biomedical engineering, environmental management and industrial applications.
Biochemical Assay Reagents  
/
HY-P0058S Pramlintide-(Ala-13C3,15N)
Pramlintide-(Ala-13C3,15N) is the 13C- and 15N-labeled Pramlintide. Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer.
Isotope-Labeled Compounds   Amylin Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-N7697R Chitotetraose tetrahydrochloride (Standard)
Butylate (Standard) is the analytical standard of Butylate. This product is intended for research and analytical applications. Butylate is a compound involved in platelet research. Platelet activation can cause autophagy, which is partly mediated by the AMPK-MTOR pathway and is related to sphingolipid metabolism. Butylate mentioned in the study may be a tool or control substance for studying related metabolic processes.
Reference Standards   Others  
/
HY-Y0078S1 Cinnamyl Alcohol-d9
Cinnamyl Alcohol-d9 is deuterated labeled Cinnamyl Alcohole (HY-Y0045). Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, exhibits anti-obesity, antioxidant and anti-inflammatory activities.
Isotope-Labeled Compounds   Potassium Channel   NO Synthase   ERK   ROCK   AMPK   Akt   PPAR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-121467S1 Acotiamide-d4
Acotiamide-d4 (Z-338 (free base)-d4) is deuterium labeled Acotiamide. Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory.
Isotope-Labeled Compounds   Cholinesterase (ChE)  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P2046 β-Endorphin (rat)
β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction.
Opioid Receptor  
Neurological, Eye or Ear Disease  
/
HY-P10397 YHIEPV
YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is a potent and orally active peptide. YHIEPV shows anxiolytic effects. YHIEPV increases leptin sensitivity to exert its anti-obesity effects.
iGluR  
Neurological, Eye or Ear Disease   Obesity  
/
HY-P1339AS1 Orexin B, human-13C18,15N3 TFA
Orexin B, human-13C18,15N3 (Human orexin B-13C18,15N3) TFA is the 13C- and 15N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with Kis of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine.
Isotope-Labeled Compounds   Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-N6655R DL-Methionine methylsulfonium chloride (Standard)
DL-Methionine methylsulfonium chloride (Standard) (DL-MMSC (Standard)) is the analytical standard of DL-Methionine methylsulfonium chloride (HY-N6655). This product is intended for research and analytical applications. DL-Methionine methylsulfonium chloride (MMSC) is an orally effective methionine-derived sulfonium salt that promotes gastric emptying and gastrointestinal transit. DL-Methionine methylsulfonium chloride attenuates oxidative stress and inflammatory responses, and enhances anti-apoptotic (apoptosis) signaling, thereby ameliorating Sodium metabisulfite (HY-Y1326)-induced testicular dysfunction and semen quality impairment. DL-Methionine methylsulfonium chloride is applicable for research on functional dyspepsia, gastrointestinal motility, and male reproductive function injury.
Reference Standards   Amino Acid Derivatives   Apoptosis  
Digestive System Disease   Male Reproductive System Disease  
/
HY-P0090S Calcitonin-13C6,15N4 (salmon) TFA
Calcitonin-13C6,15N4 (salmon) (Salmon calcitonin-13C6,15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
CGRP Receptor  
Metabolic or Endocrine Disease  
/
HY-107542R Oleoylethanolamide (Standard)
Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
Reference Standards   Endogenous Metabolite   PPAR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P1297 CRF(6-33)(human)
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.
CRFR  
Neurological, Eye or Ear Disease  
/
HY-139201E Poly-D-lysine hydrobromide (MW 150000-300000)
Poly-D-lysine hydrobromide (MW 150000-300000) is a synthetic polymer composed of D-lysine residues and is one of the most widely used matrices in neural cell culture applications. Poly-D-lysine hydrobromide (MW 150000-300000) can be used as a non-specific cell adhesion enhancer. Poly-D-lysine hydrobromide (MW 30000-70000) is an orally active CaSR agonist peptide that indirectly activates the 5-HT₃ receptor signaling pathway, delaying gastric emptying and thereby slowing the rate at which glucose enters the small intestine and is absorbed.
CaSR   5-HT Receptor  
Glucose Metabolism  
/
HY-P4928A Biotinyl-Amylin (mouse, rat) TFA
Biotinyl-Amylin (mouse, rat) TFA is a biotinylated Amylin (mouse, rat). Amylin (mouse, rat) is a 37-aminoacid pancreatic protein that exerts control over several metabolic events such as glycemia and lacticemia.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-113261S Oleoylcarnitine-d9
Oleoylcarnitine-d9 is deuterium labeled Oleoylcarnitine. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-W115727E Polyacrylamide,average Mn 150000
Polyacrylamide, average Mn 150000 (PAM, average Mn 150000) is a versatile, high-molecular-weight polyacrylamide copolymer. Polyacrylamide series materials can maintain enzyme activity in enzyme immobilization, act as drug carriers to achieve controlled release, serve as smart materials responding to temperature/pH stimuli, and be used for in vitro toxin adsorption and soft tissue filling through mechanisms such as physical entrapment, covalent binding or chemical crosslinking. Polyacrylamide finds applications in biomedical engineering, environmental management and industrial applications.
Biochemical Assay Reagents  
/
HY-P0014S2 Liraglutide-13C6,15N TFA
Liraglutide-13C6,15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds  
/
HY-107542S Oleoylethanolamide-d4
Oleoylethanolamide-d4 is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
Isotope-Labeled Compounds   Endogenous Metabolite   PPAR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P10377 GUB03385
GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC50: 0.4 nM) and NPFF2R (partial agonist, EC50: 20 nM). GUB03385 has anti-obesity effect.
Neuropeptide FF Receptor  
Metabolic or Endocrine Disease  
/
HY-P991181 VTX-1218
VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types.

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-114118S1 Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P3586 HKPao
HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles.
Apoptosis  
Cancer  
/
HY-P4928 Biotinyl-Amylin (mouse, rat)
Biotinyl-Amylin (mouse, rat) is a biotinylated Amylin (mouse, rat). Amylin (mouse, rat) is a 37-aminoacid pancreatic protein that exerts control over several metabolic events such as glycemia and lacticemia.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-P3617 Glucagon (22-29)
Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca2+ pump in liver plasma membranes independently of adenylate cyclase activation.
GCGR  
Metabolic or Endocrine Disease  
/
HY-111614S2 Melengestrol acetate-d3
Melengestrol acetate-d3 is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research.
Isotope-Labeled Compounds   Progesterone Receptor  
Metabolic or Endocrine Disease  
/
HY-P10956 Colulintide
Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity.
Amylin Receptor   CGRP Receptor  
Type 2 Diabetes   Obesity  
/
HY-N6655 DL-Methionine methylsulfonium chloride
DL-Methionine methylsulfonium chloride (DL-MMSC) is an orally effective methionine-derived sulfonium salt that promotes gastric emptying and gastrointestinal transit. DL-Methionine methylsulfonium chloride attenuates oxidative stress and inflammatory responses, and enhances anti-apoptotic (apoptosis) signaling, thereby ameliorating Sodium metabisulfite (HY-Y1326)-induced testicular dysfunction and semen quality impairment. DL-Methionine methylsulfonium chloride is applicable for research on functional dyspepsia, gastrointestinal motility, and male reproductive function injury.

Source: milk

Amino Acid Derivatives   Apoptosis  
Digestive System Disease   Male Reproductive System Disease  
/
HY-P990013 Gulgafafusp alfa
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R.

Species: Human

GCGR  
Metabolic or Endocrine Disease  
/
HY-P10018 Bamadutide
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes.
GLP Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-W002116 Methyl syringate
Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis.

Source: honey

TRP Channel   COX   Phosphatase   Bacterial  
Metabolic or Endocrine Disease   Lung Cancer   Gastric Cancer   Bacterial Infection   Pain   Rheumatoid Arthritis  
/
HY-W115727A Polyacrylamide,Anion,Mw 14-16 million
Polyacrylamide, Anion, Mw 14-16 million is a multifunctional high molecular weight anionic polyacrylamide copolymer. The anionic properties of Polyacrylamide, Anion, Mw 14-16 million enable it to be used as a flocculant to achieve charge neutralization and aggregation, while its high molecular weight properties provide viscoelastic properties for fluid applications. Polyacrylamide series materials can maintain enzyme activity in enzyme immobilization, achieve controlled release as a drug carrier, respond to temperature/pH stimulation as a smart material, and can also be used for in vitro toxin adsorption and soft tissue filling through mechanisms such as physical embedding, covalent bonding or chemical cross-linking. Polyacrylamide can be used in biomedical engineering, environmental management and industrial applications.
Biochemical Assay Reagents  
/
HY-114118S Semaglutide-d8
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-W115727B Polyacrylamide,Anion,Mw 18 million
Polyacrylamide,Anion,Mw 18 million (PAM,Anion,Mw 18 million) is a multifunctional high molecular weight anionic polyacrylamide copolymer. The anionic properties of Polyacrylamide,Anion,Mw 18 million enable it to be used as a flocculant to achieve charge neutralization and aggregation, while its high molecular weight properties provide viscoelastic properties for fluid applications. Polyacrylamide series materials can maintain enzyme activity in enzyme immobilization, act as drug carriers to achieve controlled release, serve as smart materials responding to temperature/pH stimuli, and be used for in vitro toxin adsorption and soft tissue filling through mechanisms such as physical entrapment, covalent binding or chemical crosslinking. Polyacrylamide finds applications in biomedical engineering, environmental management and industrial applications.
Biochemical Assay Reagents  
/
HY-P990961 Palverafusp alfa
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer.

Species: Human

VEGFR   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-119720 Neocryptotanshinone
Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza, inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathways.
NF-κB   NO Synthase  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis  
/
HY-W250120 Konjac glucomannan (Viscosity≥15000mPa.s)
Konjac glucomannan (Viscosity≥15000mPa.s) is an orally active acetylated (1-4)-β-D-glucomannan with multiple biological activities including anti-diabetic, anti-obesity, anti-inflammatory effects, as well as film-forming and gelling properties. Konjac glucomannan (Viscosity≥15000mPa.s) forms a defensive coating on the intestinal surface, reducing levels of blood glucose, cholesterol, triglycerides and blood pressure; it is specifically degraded by colonic β-mannanase produced by human colonic bacteria. Konjac glucomannan (Viscosity≥15000mPa.s) can be used as a food additive, dietary supplement and excipient for oral colon-targeted drug delivery systems. Konjac glucomannan (Viscosity≥15000mPa.s) is applicable to research related to various diseases such as type 2 diabetes, obesity, atopic dermatitis and metabolic syndrome, as well as research in fields including biotechnology, pharmaceuticals and tissue engineering.
Biochemical Assay Reagents   Drug Intermediate  
Atopic Dermatitis   Type 2 Diabetes   Obesity  
/
HY-P0014S1 Liraglutide-13C5,15N tetraTFA
Liraglutide-13C6,15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GCGR   GLP Receptor  
/
HY-P3469A Dasiglucagon acetate
Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research.
GCGR  
Metabolic or Endocrine Disease  
/
HY-P10927 BRP
BRP is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP is applicable to obesity-related research.
AP-1   PKA  
Obesity  
/
HY-P0150 Glucagon (19-29), human
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
GCGR  
Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation  
/
HY-114118CP Semaglutide (crude)
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P99383 Volagidemab
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).

Species: Human

GCGR  
Metabolic or Endocrine Disease  
/
HY-P99357 Crotedumab
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes.

Species: Human

GCGR  
Metabolic or Endocrine Disease  
/
HY-114118S3 Semaglutide-13C6,15N TFA
Semaglutide-13C6,15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Metabolic or Endocrine Disease  
/
HY-Y0079 D-Phenylalanine
D-Phenylalanine is an atypical D-amino acid and an inhibitor of bacterial biofilm formation. D-Phenylalanine mainly replaces D-alanine (D-Ala) by incorporating into the fourth and fifth positions of bacterial peptidoglycan (PG), changing the cell wall structure, enhancing bacterial acid resistance and affecting biofilm formation. D-Phenylalanine may promote the secretion of peptide tyrosine tyrosine (PYY) in mammals by activating the intestinal GPR109B receptor. D-Phenylalanine can inhibit the maturation of microbial biofilms and promote the release of specific hormones. It can be used for antibacterial preservation, improving the yield of probiotics in the food industry, and studying appetite regulation and blood sugar control in metabolic diseases such as diabetes.
Endogenous Metabolite  
Bacterial Infection   Glucose Metabolism  
/
HY-P1393 AC 187
AC 187 is a potent and orally active amylin receptor antagonist with an IC50 of 0.48 nM and a Ki of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-P99203 Cemiplimab
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-113261 Oleoylcarnitine
Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation.
Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P1024 GLP-2(1-33)(human)
GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the GLP-2 receptor and stimulate the growth of intestinal epithelium.
GCGR  
Metabolic or Endocrine Disease  
/
HY-P10745A Petrelintide acetate
Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research.
Amylin Receptor  
Type 2 Diabetes  
/
HY-P1070A Amylin, amide, human TFA
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-P11245A NN1213 acetate
NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-P990802 Anti-Mouse CD3ε Antibody (145-2C11)
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305).

Species: Mouse

CD3  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P10798A Eloralintide sodium
Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca2+ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity.
Amylin Receptor   Calcium Channel  
Obesity  
/
HY-P11274A Zenagamtide sodium
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   Insulin Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-P10745 Petrelintide
Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research.
Amylin Receptor  
Type 2 Diabetes  
/
HY-P0058 Pramlintide
Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer.
Amylin Receptor  
Cancer   Glucose Metabolism  
/
HY-P0058B Pramlintide acetate
Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer.
Amylin Receptor  
Cancer   Glucose Metabolism  
/
HY-P1070 Amylin, amide, human
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-P10798 Eloralintide
Eloralintide (LY-3841136) is an amylin receptor agonist with human AMY1R EC50 23.9 pM and human AMY3R EC50 253.8 pM. Eloralintide induces decreased appetite, reduced food intake, body weight and fat mass loss, prolonged plasma calcium2+ reduction, and weak conditioned taste avoidance. Eloralintide can be used for the research of obesity.
Amylin Receptor   Calcium Channel  
Obesity  
/
HY-P72240 IAPP Protein, Human (GST)
The IAPP protein selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, affecting glucose metabolism without affecting adipocytes. IAPP interacts with IDE (insulin-degrading enzyme) and insulin (INS) to form homodimers, affecting their fibril formation. IAPP Protein, Human (GST) is the recombinant human-derived IAPP protein, expressed by E. coli , with N-GST labeled tag.

Species: Human; Source: E. coli

/
HY-P70352 GLP1R Protein, Human (HEK293, Fc)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, Fc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P700411 GCGR Protein, Human (HEK293, N-His, C-Myc)
The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GCGR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor

/
HY-P703992 GCGR Protein, Human (HEK293, hFc)
The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, hFc) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-hFc labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs)

/
HY-P78702 GCGR/Glucagon receptor Protein, Mouse (HEK293, Fc)
GCGR/glucagon receptor protein is a G protein-coupled receptor for glucagon that centrally regulates blood glucose levels. It plays a key role in the fasting response by actively regulating hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. GCGR/Glucagon receptor Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived GCGR/Glucagon receptor protein, expressed by HEK293 , with C-hFc labeled tag. The total length of GCGR/Glucagon receptor Protein, Mouse (HEK293, Fc) is 111 a.a., with molecular weight of 50-65 kDa.

Species: Mouse; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor

/
HY-P703987 GCGR Protein, Human (HEK293, His, Avi)
The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, His, Avi) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-Avi and C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins

/
HY-P704531 IAPP Protein, Human (P. pastoris, His)
The IAPP protein selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, affecting glucose metabolism without affecting adipocytes. IAPP interacts with IDE (insulin-degrading enzyme) and insulin (INS) to form homodimers, affecting their fibril formation. IAPP Protein, Human (P. pastoris, His) is the recombinant human-derived IAPP protein, expressed by P. pastoris, with N-6*His labeled tag.

Species: Human; Source: P. pastoris

/
HY-P704626 GCGR Protein, Human (HEK293, His)
The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, His) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor

/
HY-P704627 GCGR Protein-VLP, Human (HEK293)
GCGR Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor

/
HY-P705157 GCGR Protein, Human (Biotinylated, HEK293, His-Avi)
The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-Avi/C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Biotinylated Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor

/
HY-P705976 GCGR Protein, Rat (HEK293, His)

Species: Rat; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor

/
HY-P80317 S100A4 Antibody (YA084)
S100A4 Antibody (YA084) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100A4.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87875 Glucagon Antibody (YA7560)
Glucagon Antibody (YA7560) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Glucagon.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85994 Glucagon Antibody (YA5686)
Glucagon Antibody (YA5686) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Glucagon.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P810878 Glucagon Receptor Antibody
Glucagon Receptor Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Glucagon Receptor.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P811065 GLP-1 Receptor Antibody
GLP-1 Receptor Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to GLP-1 Receptor.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P81242 Glucagon Antibody (YA921)
Glucagon Antibody (YA921) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Glucagon.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85183 Glucagon Antibody (YA4875)
Glucagon Antibody (YA4875) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Glucagon.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85626 S100A4 Antibody (YA5318)
S100A4 Antibody (YA5318) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to S100A4.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85626A S100A4 Antibody (YA5318)(PBS only)
S100A4 Antibody (YA5318) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to S100A4.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/

Keywords

amylin | obesity treatment | amylin receptor agonist | cagrilintide | pramlintide | eloralintide | weight management | appetite regulation | satiation | gastric emptying | glucagon suppression | metabolic control | amylin analogues | CagriSema | anti-obesity pharmacotherapy